Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM1015 in Advanced Solid Tumors
NCT05950815Phase 1Unknown
- Sponsor
- Biotheus
- Start
- May 2022
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PM1015 in solid tumor, sponsored by Biotheus. Primary endpoints: Dose Limited Toxicity at 21 days and Treatment-related adverse events. Status: unknown.
02
Drugs
PM1015
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05950815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05950815.